

ForPatients

by Roche

Juvenile Idiopathic Arthritis

A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA)

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT03301883 YA39368

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This Phase IV, multicenter, single-arm, open-label study will evaluate the efficacy and safety of tocilizumab in Chinese participants with sJIA with persistent activity and an inadequate response to non-steroidal anti-inflammatory drugs (NSAIDs) and steroid therapy.

Hoffmann-La Roche
Sponsor

Phase 4
Phase

NCT03301883 YA39368
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥ 2 Years & ≤ 17 Years

Healthy Volunteers
No
